Neogen (NEOG) 44th Annual J.P. Morgan Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
44th Annual J.P. Morgan Healthcare Conference summary
15 Jan, 2026Market Overview and Industry Trends
Food safety and animal health markets are expanding due to increased food complexity, stricter regulations, and higher consumer expectations.
Regulatory mandates, not government funding, drive demand for food safety solutions, providing a stable market tailwind.
The addressable market is estimated at $11B, with strong growth potential across USAC, EMEA, LATAM, and APAC regions.
The company holds market leadership in pathogen detection and hygiene indicators, serving a broad customer base from small processors to global protein producers.
Innovation cycles are faster in food safety compared to human diagnostics due to lower regulatory hurdles.
Strategic Direction, Vision, and Turnaround Plan
The vision is to fuel global food security with a safe, sufficient, and sustainable food supply.
A new management team with turnaround experience has been assembled, restructuring the executive team for speed, accountability, and cross-functional execution.
The turnaround and growth strategy follows three phases: stabilize, accelerate, and expand, with a focus on top-line growth, cost management, and operational transformation.
Execution discipline, customer intimacy, and operational maturity are key to achieving market-leading performance.
Enhanced governance and controls are in place to improve cash predictability and risk management.
Portfolio Focus and Innovation
The portfolio is being refocused on higher-growth, more profitable markets, with divestiture of the genomics division expected by year-end.
PetrifilmⓇ, the flagship product, is central to the food safety offering, with a new production site in Lansing, Michigan, on track for completion by November 2026.
High-growth consumables include PetrifilmⓇ, pathogen testing, and biosecurity, with market CAGRs up to 12%.
Innovation is customer-need driven, with increased R&D and CapEx investment focused on scalable, high-return projects and a low-teens New Product Vitality Index.
End-to-end food safety solutions integrate products, analytics, and expert services, reinforcing brand authority and customer loyalty.
Latest events from Neogen
- Q4 revenue fell 2.1% as integration neared completion; FY25 targets core growth and margin gains.NEOG
Q4 20242 Feb 2026 - Integration nears completion as innovation and global expansion drive strong growth prospects.NEOG
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Operational recovery and integration progress set the stage for growth and margin expansion.NEOG
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q1 revenue and margins fell, but guidance and integration priorities remain intact.NEOG
Q1 202519 Jan 2026 - Q2 revenue hit $230M, integration advances, and international growth accelerates.NEOG
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Goodwill impairment drives $456M net loss despite core growth and margin actions.NEOG
Q2 202510 Jan 2026 - Integration progress and innovation drive growth amid regulatory momentum and portfolio actions.NEOG
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q2 FY26 delivered 2.9% core growth, margin gains, and raised guidance amid ongoing headwinds.NEOG
Q2 20268 Jan 2026 - Q3 revenue fell 3% and a $461M impairment led to a net loss and lower FY25 guidance.NEOG
Q3 202524 Dec 2025